Publish Date: February 28, 2017
Immunoprecise Appoints Contact Financial for Investor Relations and Launches New Website For Its Custom Antibody Services
Victoria, British Columbia, Canada, March 1, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: TQURF), a life sciences technology and product company engineering custom antibodies, announced that it has appointed Contact Financial (“Contact”) as its investor relations firm. Contact will assist the Company with the development and execution of a comprehensive strategic communications program.
Contact Financial is a Vancouver-based firm specializing in assisting emerging growth companies with media relations, capital markets experience, brand building/awareness and developing strategies to strengthen relations and communications between companies or individuals associated with the firm. Contact Financial will assist ImmunoPrecise in gaining increased exposure to investors through the dissemination of corporate information to a network of online venues, brokerage firms, financial institutions and private investors.
“We are excited to present ImmunoPrecise to our investor ecosystem,” stated Kirk Gamley, President and CEO of Contact Financial. “ImmunoPrecise’s experienced team operates a profitable enterprise that is growing and coupled with industry tailwinds, will garner significant attention among investors.”
Contact Financial has been appointed for an initial term of six (6) months, which can be extended on a monthly basis as confirmed by the Company. Contact Financial will be paid for provision of its services a monthly fee of CAD $4,000.00 (plus GST), subject to the approval of the TSX Venture Exchange.
Other than 120,000 common shares held directly and indirectly by Kirk Gamley and Contact Financial, none of the Contact Financial group has any interest, directly or indirectly, in the Company or its securities, although it may choose to acquire shares in the Company in the future. Contact Financial does not intend to undertake any market making activities.
The Company is also pleased to report the launch of its newly designed corporate website and invite visitors to explore it at www.ipatherapeutics.com.
The objective of the new design is intended to create a superior user interface with a cleaner look, simplified navigation and additional functionality allowing customers to enter information that can expedite the scoping of work and project quoting process.
The website has been reorganized in a way that highlights the specific services ImmunoPrecise offers. The branding platform of the Company’s customized antibody design service offerings will be more evident, clearly outlined, and consistent throughout the website. Furthermore, the state-of-the-art website uses the latest technology making it compatible with current web browsers and will adapt to the different screen sizes of various mobile devices.
The brand new site is constructed for both potential new clients and returning research partners. Clients can receive expedited quotes and reduce project-scoping time by entering information directly into a web form on the new site. Importantly, the newly designed website is created to be flexible and be able to add new products and services.
“We intend to aggressively grow our footprint in the lucrative antibody research space,” stated Tom D’Orazio, President and CEO of ImmunoPrecise. “Additionally, we are talking to potential partners about acquiring complementary services that combine with our strong presence in custom antibody engineering. The new website will allow us to quickly and seamlessly add new areas.”
Please visit our website for more information and provide feedback on your experience.
Customers can learn more about rabbit monoclonal antibody design at the following link: https://ipaprod.wpengine.com/services/rabbit-monoclonal-antibodies/
For direct access to information about the proprietary Rapid Prime™ monoclonal antibody service in mice, go to the following link: https://ipaprod.wpengine.com/services/monoclonal-development/monoclonal-rapid/
ImmunoPrecise is a life sciences product and technology company engineering custom antibodies for the global research and industrial community. The Company uses proprietary innovative inoculation and cloning technologies and established expertise to produce monoclonal antibodies significantly faster than traditional methods of antibody production. Since its inception in 1989, it has used these capacities to produce hundreds of monoclonal antibodies now sold commercially through industry partners.
ImmunoPrecise is headquartered in Victoria, British Columbia and has its own in-house animal care unit, tissue culture facility and molecular facility. To learn more about ImmunoPrecise, please visit www.ipatherapeutics.com
About Contact Financial
Contact Financial is a broad-based strategic marketing and communications firm with experience in creating exposure for small to mid-cap companies. Contact Financial’s services include providing advice with respect to corporate development, production and distribution of investor-focused communication tools, and increasing awareness within the financial community. Contact Financial has offices in both Vancouver and Montreal, and is owned by Kirk Gamley. www.contactfinancial.com
For further information please contact:
ImmunoPrecise Antibodies Ltd.
Unit 3204 – 4464 Markham Street
Victoria, BC V8Z 7X8, Canada
For investor relations please contact:
Contact Financial Corp.
1450 – 701 West Georgia St.
Vancouver, BC V7Y 1G5
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. ImmunoPrecise uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things: risks and uncertainties described in the Company’s Filing Statement dated December 13, 2016 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, the Company undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.